source
- STAT+: Preliminary trial results suggest a path to a safer Alzheimer’s treatmentProMIS Neurosciences is trying to design a safer amyloid-clearing drug for Alzheimer's. Early results suggest it might be on to something.
- GSK prepares for patent cliff with $2.5B cost-cutting planThe pharma hasn’t yet revealed what kind of job cuts might be involved in the plan, which will help it absorb the coming loss of patents important to its HIV drug franchise.